Exhibit 99.1 FOR IMMEDIATE RELEASE INVESTOR CONTACT: MEDIA CONTACT: Frank Morgan Harlow Sumerford 615-344-2688 615-344-1851 ● Revenues totaled $17.492 billion ● Net income attributable to HCA Healthcare, Inc. totaled $1.461 billion, or $5.53 per diluted share ● Adjusted EBITDA totaled $3.550 billion ● Cash flows from operating activities totaled $1.971 billion ● Same facility admissions increased 5.8 percent while same facility equivalent admissions increased 5.2 percent Same facility admissions increased 5 ...

For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Has HCA Healthcare (HCA) been one of those stocks this year? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question. HCA Healthcare is one of 1025 individual stocks in the Medical sector. Collectively, these companies sit at #4 in the Zacks Sector Rank. The Zacks Sector Rank includes 16 different ...

The Zacks Consensus Estimate for second-quarter earnings per share of $4.97 indicates a 15.9% increase from the prior-year figure of $4.29. The estimate increased 6 cents in the past 30 days. The consensus estimate for second-quarter revenues of $17.1 billion indicates 7.9% growth from the year-ago reported figure. HCA Healthcare beat the consensus estimate for earnings in three of the prior four quarters, missing once, with the average being 5.6%. Earnings Whispers Earnings ESP: HCA Healthcare has an Earni ...

The market expects HCA Healthcare (HCA) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended June 2024. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates. Zacks Consensus Estimate Estimate Revisions Trend Earnings Whisper A positive Earnings ESP is a strong predictor of an earnings be ...

These companies have what it takes to stand the test of time in a portfolio. 1. Vertex Pharmaceuticals The company has its sights set on the launch of several potential blockbusters before the end of the decade. These include a new triple-combination therapy for cystic fibrosis, which was just granted priority review by the U.S. Food and Drug Administration with a Prescription Drug User Fee Act (PDUFA) target action date of Jan. 2, 2025. No industry is totally impervious to market dynamics, but healthcare c ...

If you are looking for a stock that has a solid history of beating earnings estimates and is in a good position to maintain the trend in its next quarterly report, you should consider HCA Healthcare (HCA) . This company, which is in the Zacks Medical - Hospital industry, shows potential for another earnings beat. This hospital operator has an established record of topping earnings estimates, especially when looking at the previous two reports. The company boasts an average surprise for the past two quarters ...

The research service features daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, all of which will help you become a smarter, more confident investor. Each stock is given an alphabetic rating of A, B, C, D or F based on their value, growth, and momentum qualities. With this system, an A is better than a B, a B is better than a C, and so on, meaning the better the score, the better chance the stock will outperfor ...

Zacks Rank & Price Performance The stock has gained 25.9% year to date compared with the industry's 24.9% growth. The Medical sector and the S&P 500 composite index have increased 4.5% and 6.9%, respectively, in the same time frame. Favorable Style Score Robust Growth Prospects The consensus mark for 2025 earnings is pegged at $23.19 per share, indicating 10.9% growth from the 2024 estimate. The same for revenues is $73.2 billion, implying 5.1% growth from the 2024 estimate The Zacks Consensus Estimate for ...

No investment in the equity markets (or anywhere else, for that matter) is entirely risk-free. However, some stocks look safe enough to allow investors to rest easy at night, knowing the shares are highly unlikely to experience significant losses. Though corporations in this category tend to have less upside potential, they have a place in the portfolios of investors with a long-term mindset. A company doesn't last for more than a hundred years by accident. Johnson & Johnson has been around that long and ha ...

Based on their value, growth, and momentum characteristics, each stock is assigned a rating of A, B, C, D, or F. The better the score, the better chance the stock will outperform; an A is better than a B, a B is better than a C, and so on. Momentum trading is all about taking advantage of upward or downward trends in a stock's price or earnings outlook, and these investors live by the saying "the trend is your friend." The Momentum Style Score can pinpoint good times to build a position in a stock, using fa ...